GSK PLC (NYSE:GSK)
$ 34.08 -0.04 (-0.12%) Market Cap: 69.61 Bil Enterprise Value: 84.95 Bil PE Ratio: 21.96 PB Ratio: 3.90 GF Score: 71/100

GlaxoSmithKline PLC at Cowen Health Care Conference (Virtual) Transcript

Mar 07, 2022 / 04:10PM GMT
Release Date Price: $40.57 (-1.79%)
Stephen Michael Scala
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

Good morning, and welcome once again. We are here with the top management of GlaxoSmithKline at Cowen's 42nd Annual Healthcare Conference. We're very, very pleased to have with us Dr. Hal Barron, who is Chief Scientific Officer and President of Research and Development. Dr. Barron has shown over the last 30 or so years that he's clearly one of the industry's most prolific drug development experts. So it's always great to have conversations with him.

Questions & Answers

Stephen Michael Scala
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

So Hal, thanks again for your time this morning. I'd like to start out and ask, what have -- do you believe, have been your greatest accomplishments in R&D since joining GSK a little over 4 years ago?

Hal V. Barron
GlaxoSmithKline plc - Chief Scientific Officer, President of R&D and Director

Yes. Thanks, Steve. Thanks for having me. I

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot